NCT00758160
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
See it on ClinicalTrials.gov ↗296 people
16.6%
83.4%
49 womenmiddle line = equal numbers247 men
- Phase
- PHASE4
- Paid for by
- Johnson & Johnson Taiwan Ltd
- Finished
- 2008-06
- Health conditions
- Attention Deficit Disorder With Hyperactivity
- Who could join
- Anyone
- Ages
- 6 Years – 18 Years
- Average age
- mean 9.5 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 18 Years.”
- No seizures
Women with epilepsy or past seizures were turned away.
“Participants who have glaucoma (increased pressure inside the eye that causes visual problems), an ongoing seizure disorders, or a psychotic disorder”
Study titles and rules are shown in their original English.